Download Files:
DNQX
$66 – $238
Products Details
Product Description
– DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively)[1].
Web ID
– HY-15067
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C8H4N4O6
References
– [1]Honoré T, et al. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science. 1988;241(4866):701-703.|[2]Lee SH, et al. Selective excitatory actions of DNQX and CNQX in rat thalamic neurons. J Neurophysiol. 2010;103(4):1728-1734.|[3]Sharp JW, et al. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex. Brain Res. 1995;687(1-2):114-124.
CAS Number
– 2379-57-9
Molecular Weight
– 252.14
Compound Purity
– 99.26
SMILES
– O=C1C(NC2=CC([N+]([O-])=O)=C([N+]([O-])=O)C=C2N1)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : ≥ 35 mg/mL|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– iGluR
Isoform
– AMPA Receptor;Kainate Receptor
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
